HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G/Clarins deal

This article was originally published in The Rose Sheet

Executive Summary

Clarins Fragrance Group will distribute fragrances under the Valentino label in the U.S. under deal with Procter & Gamble, effective immediately, firms announce. Clarins, which distributes P&G's Jean Patou and Lacoste fragrances in specialty stores, department stores and boutiques, maintains it is well suited to distribute the specialty-door Valentino brand. P&G's Prestige Beaute division recently signed a licensing agreement with the Italian designer Valentino to market the brand's fragrances and beauty products (1"The Rose Sheet" Aug. 4, 2003, In Brief)...

You may also be interested in...



Valentino license

Procter & Gamble Prestige Beauté, the beauty division's fine fragrance unit, signed a licensing agreement with Italian fashion designer Valentino to market fragrance and beauty products under the designer name effective Aug. 1, company announces July 30. Valentino license has global growth potential, P&G says, noting agreement is in line with corporate strategy to "develop faster-growing, higher margin, more asset efficient businesses with global leadership potential." Valentino brand has feminine, glamorous heritage that will complement P&G's existing fine fragrance portfolio, firm says. Lineup, which currently includes Hugo Boss, Jean Patou and Lacoste, also will be expanded with addition of Wella fragrance brands. Valentino fragrances previously were marketed by Unilever Prestige...

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011530

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel